Debt FinancingMDAI's cash position improved to $14.1 million, which includes $8.5 million in new debt, helping the company to move towards commercial revenue with existing cash.
Regulatory Approval TimelineThe company expects to submit DeepView to the FDA by the end of the second quarter of 2025, with approval anticipated in early fiscal year 2026.
Revenue GuidanceManagement provided 2025 revenue guidance of approximately $21.5M, an expected decrease from 2024, as the company intends to focus its efforts primarily on obtaining regulatory approval.